Real-world Study for the Safety of Albumin-Bound Paclitaxel in Malignant Tumors
Launched by CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY CO., LTD. · Aug 14, 2019
Trial Information
Current as of June 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • In patients with malignant tumor who have been treated with albumin-bound paclitaxel for the treatment.
- Exclusion Criteria:
- • No
About Cspc Zhongqi Pharmaceutical Technology Co., Ltd.
CSPC Zhongqi Pharmaceutical Technology Co., Ltd. is a leading biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapeutic solutions. With a strong focus on advancing healthcare, the company specializes in the development of high-quality pharmaceuticals across various therapeutic areas, including oncology, cardiovascular, and infectious diseases. Leveraging cutting-edge technology and a commitment to scientific excellence, CSPC Zhongqi aims to enhance patient outcomes through rigorous clinical trials and the introduction of effective treatments that address unmet medical needs. Their robust pipeline and strategic partnerships underscore their position as a key player in the global pharmaceutical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Xi'an, Shanxi, China
Zhengzhou, Henan, China
Hefei, Anhui, China
Hangzhou, Zhejiang, China
Zhengzhou, Henan, China
Shijiazhuang, Hebei, China
Haikou, Hainan, China
Shenyang, Liaoning, China
Beijing, , China
Hefei, Anhui, China
Harbin, Heilongjiang, China
Hohhot, Inner Mongolia Autonomous Region, China
Taiyuan, Shanxi, China
Xi'an, Shanxi, China
Maanshan, Anhui, China
Patients applied
Trial Officials
Wei Zhao
Study Director
Shiyao Group Ouyi Pharmaceutical Co., Ltd.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials